EXPLORE!

FDA Approves Revumenib for Acute Leukemia

  416 Views

Emedinexus    18 November 2024

The FDA has approved revumenib for relapsed or refractory acute leukemia with a KMT2A translocation in patients aged 1 year and older, offering a targeted therapy for this genetic subtype.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.